{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient events observed","groupId":"OG000","lowerLimit":"14.9","upperLimit":"NA","value":"94.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from first dose until death due to any cause. Censoring was performed using the date of last known contact for those who were alive at the time of analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG000","title":"Adenocarcinoma of the Small Intestine (ASI)"}],"paramType":"MEDIAN","populationDescription":"ITT/Evaluable population - Primary analysis cohort","reportingStatus":"POSTED","timeFrame":"From study treatment start date until date of death from any cause, assessed up to 92 months (cut-off date for end of study = 10-Dec-21)","title":"Overall Survival (OS) in the Adenocarcinoma of the Small Intestine (ASI) Cohort","type":"SECONDARY","unitOfMeasure":"Weeks"}